Filing Details

Accession Number:
0000899243-22-013752
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-05 16:16:13
Reporting Period:
2022-04-01
Accepted Time:
2022-04-05 16:16:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1466301 Clovis Oncology Inc. CLVS Pharmaceutical Preparations (2834) 900475355
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1834833 C. Thomas Harding C/O Clovis Oncology, Inc.
5500 Flatiron Parkway, Suite 100
Boulder CO 80301
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-04-01 16 $0.00 2,838 No 4 M Indirect By wife
Common Stock Disposition 2022-04-04 7 $2.66 2,831 No 4 S Indirect By wife
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect By wife
No 4 S Indirect By wife
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2022-04-01 16 $0.00 16 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
140 No 4 M Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 11,654 Direct
Footnotes
  1. Each Restricted Stock Unit represents the right to receive one share of Common Stock.
  2. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
  3. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.